Q-omics provides the consensus-scored SLC6A14 profile across patient tissues and cancer cell-line models. SLC6A14 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC6A14 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SLC6A14 RNA expression shows 11,764 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, COAD, and LSCC as cancer lineages where SLC6A14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A14 survival associations across molecular data types. SLC6A14 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A14 RNA expression–survival associations across cancer types. High SLC6A14 expression shows unfavorable associations in KIRC, KIRP, LUAD, ACC and PAAD, but favorable associations in MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC6A14 RNA expression.
This table summarizes SLC6A14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A14 shows lower tumor expression in LUSC and BRCA and higher tumor expression in COAD, THCA, STAD and UCEC. The COAD box plot shows higher SLC6A14 RNA expression in tumor versus normal tissue (log2 FC = +1.795, t-test p < 0.001).
This table shows molecular features associated with SLC6A14 in patient tissues and cancer cell lines. In patient samples, SLC6A14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
